Evidence map›Paper›PMID 35473538›Full record

ArticleAnti-cancer agents in medicinal chemistry2022

Antitumor Effects of Turmeric on OVCAR-3 Ovarian Cancer Cell Lines.

Hulusi Goktug Gurer, Ozlem Ozgur Gursoy, Ceren Yildiz Eren, Canan Vejselova Sezer

Open access · hybridAbstract read
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Integrating Chemo- and Bioinformatics withJournal of chemical information and modeling · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Hulusi Goktug GurerEskisehir Acibadem Hospital, Obstetrics and Gynecology Clinic, Eskisehir, Turkey.
Ozlem Ozgur GursoyEskisehir Acibadem Hospital, Obstetrics and Gynecology Clinic, Eskisehir, Turkey.
Ceren Yildiz ErenEskisehir Acibadem Hospital, Obstetrics and Gynecology Clinic, Eskisehir, Turkey.
Canan Vejselova SezerDepartment of Biology, Faculty of Science, Eskişehir Technical University, Eskişehir, Turkey.
Acıbadem Adana Hospital · TREskişehir City Hospital · TREskisehir Technical University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOvarian cancer is the deadliest gynecological malignancy, usually not detected until the late stages. In vitro cell culture is a method used to study the behavior of cells in a controlled environment. Turmeric has attracted the attention of scientists due to its anticancer potential.

methodsOVCAR-3 cells were cultured in RPMI medium with 100 units/mL-100 μg/mL of penicillin-streptomycin and 10% foetal bovine serum in a CO2 incubator. Turmeric extract was diluted in DMSO. Different concentrations of turmeric extract were prepared. Annexin-V staining was performed to test the translocation of phosphatidylserine to the outer side of the cell membrane as a clear indicator of apoptosis.

resultsTurmeric extract significantly reduced the viability of OVCAR-3 cells both within 24 and 48 hours of exposure. OVCAR-3 cells were treated with IC50 concentration of turmeric extract for 24 hours. 82.60% of cells were viable. The percentages of the dead, early apoptotic, and late apoptotic cells were detected to be 0.80%, 9.70%, and 6.90%, respectively. Untreated OVCAR-3 cells had migration ability. OVCAR-3 cells exposed to an IC50 concentration of turmeric extract for 24 hours did not close the scratch area.

conclusionIn this research, anticancer effects of turmeric have been demonstrated by different analysis methods.

Indexed as

CurcumaOvarian NeoplasmsApoptosisCarcinoma, Ovarian EpithelialCell Line, TumorCell ProliferationFemaleHumansAnnexin-Vanti-cancer effectsmigration assayMTTOVCAR-3Turmeric

Identifiers

PMID35473538
PMCPMC9637976
OpenAlexW4225013442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.